Mutual of America Capital Management LLC Buys 8,421 Shares of Edwards Lifesciences Corp (EW)

Mutual of America Capital Management LLC boosted its stake in Edwards Lifesciences Corp (NYSE:EW) by 29.5% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 36,944 shares of the medical research company’s stock after acquiring an additional 8,421 shares during the period. Mutual of America Capital Management LLC’s holdings in Edwards Lifesciences were worth $4,164,000 as of its most recent SEC filing.

Other hedge funds also recently modified their holdings of the company. Koch Industries Inc. boosted its holdings in Edwards Lifesciences by 28,363.1% in the 2nd quarter. Koch Industries Inc. now owns 1,397,254 shares of the medical research company’s stock valued at $1,386,000 after purchasing an additional 1,392,345 shares in the last quarter. Atlantic Trust Group LLC boosted its holdings in Edwards Lifesciences by 734.7% in the 3rd quarter. Atlantic Trust Group LLC now owns 914,989 shares of the medical research company’s stock valued at $100,018,000 after purchasing an additional 805,370 shares in the last quarter. Janus Henderson Group PLC boosted its holdings in Edwards Lifesciences by 1,135.0% in the 3rd quarter. Janus Henderson Group PLC now owns 619,703 shares of the medical research company’s stock valued at $67,739,000 after purchasing an additional 569,525 shares in the last quarter. Old Mutual Global Investors UK Ltd. boosted its holdings in Edwards Lifesciences by 83.0% in the 3rd quarter. Old Mutual Global Investors UK Ltd. now owns 1,100,885 shares of the medical research company’s stock valued at $120,337,000 after purchasing an additional 499,436 shares in the last quarter. Finally, Wells Fargo & Company MN boosted its holdings in Edwards Lifesciences by 20.2% in the 3rd quarter. Wells Fargo & Company MN now owns 2,548,282 shares of the medical research company’s stock valued at $278,553,000 after purchasing an additional 429,022 shares in the last quarter. Hedge funds and other institutional investors own 81.52% of the company’s stock.

Edwards Lifesciences Corp (EW) opened at $129.70 on Thursday. The company has a debt-to-equity ratio of 0.15, a quick ratio of 1.41 and a current ratio of 1.81. Edwards Lifesciences Corp has a 12-month low of $89.20 and a 12-month high of $138.48. The stock has a market capitalization of $26,892.66, a P/E ratio of 45.03, a P/E/G ratio of 1.88 and a beta of 0.63.

Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings data on Thursday, February 1st. The medical research company reported $0.94 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.91 by $0.03. Edwards Lifesciences had a return on equity of 27.69% and a net margin of 18.11%. The firm had revenue of $888.50 million during the quarter, compared to the consensus estimate of $868.45 million. During the same period in the previous year, the firm posted $0.75 EPS. The company’s quarterly revenue was up 15.7% compared to the same quarter last year. analysts predict that Edwards Lifesciences Corp will post 4.49 earnings per share for the current fiscal year.

Edwards Lifesciences declared that its Board of Directors has initiated a stock buyback program on Thursday, December 7th that authorizes the company to buyback $1.00 billion in shares. This buyback authorization authorizes the medical research company to purchase shares of its stock through open market purchases. Stock buyback programs are generally a sign that the company’s board of directors believes its stock is undervalued.

In related news, VP Donald E. Bobo, Jr. sold 5,300 shares of Edwards Lifesciences stock in a transaction that occurred on Monday, January 29th. The stock was sold at an average price of $127.24, for a total transaction of $674,372.00. Following the completion of the transaction, the vice president now directly owns 24,908 shares in the company, valued at approximately $3,169,293.92. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Michael A. Mussallem sold 32,900 shares of Edwards Lifesciences stock in a transaction that occurred on Monday, November 20th. The stock was sold at an average price of $106.86, for a total value of $3,515,694.00. The disclosure for this sale can be found here. Insiders have sold a total of 175,940 shares of company stock valued at $20,049,578 over the last 90 days. Insiders own 2.13% of the company’s stock.

EW has been the topic of a number of analyst reports. SunTrust Banks reaffirmed a “buy” rating and issued a $150.00 price objective on shares of Edwards Lifesciences in a report on Wednesday, January 31st. Cowen set a $135.00 price target on Edwards Lifesciences and gave the stock a “buy” rating in a research note on Sunday, December 10th. BMO Capital Markets reissued a “buy” rating and set a $137.00 price target on shares of Edwards Lifesciences in a research note on Friday, December 8th. Canaccord Genuity reissued a “buy” rating and set a $137.00 price target on shares of Edwards Lifesciences in a research note on Wednesday, November 29th. Finally, Stifel Nicolaus reissued a “buy” rating and set a $155.00 price target on shares of Edwards Lifesciences in a research note on Friday, February 2nd. Four equities research analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has given a strong buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average target price of $139.25.

TRADEMARK VIOLATION NOTICE: “Mutual of America Capital Management LLC Buys 8,421 Shares of Edwards Lifesciences Corp (EW)” was first published by Community Financial News and is the property of of Community Financial News. If you are accessing this article on another domain, it was stolen and republished in violation of U.S. & international copyright law. The original version of this article can be viewed at https://www.com-unik.info/2018/02/08/mutual-of-america-capital-management-llc-buys-8421-shares-of-edwards-lifesciences-corp-ew.html.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation is a manufacturer of heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. The Company is engaged in patient-focused innovations for structural heart disease and critical care monitoring. Its segments include United States, Europe, Japan and Rest of World.

Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Corp (NYSE:EW).

Institutional Ownership by Quarter for Edwards Lifesciences (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit